海外の治験の状況「COVID-19」での検索結果
70件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Evaluation, chez des femmes atteintes d’un cancer du sein non métastatique recevant un traitement antihormonal adjuvant, de l’efficacité d’un traitement homéopathique par BRN-01 versus placebo dans le traitement des bouffées de chaleur - HBC
- Femmes adultes, atteintes de cancer du sein prouvé histologiquement, non métastatique, pour lequel elles suivent un traitement anti-hormonal (par anti-aromatase ou tamoxifène) depuis au moins un mois, et souffrant de bouffées de chaleur et/ou sueurs nocturnes quotidiennes et invalidantes. MedDRA version: 9.1 Level: LLT Classification code 10057654 Term: Breast cancer female
- France
- 2009-07-02
Not Recruiting
- Systemic and local estrogen metabolism in healthy women compared to endometrial cancer patients
- endometrial cancer estrogen metabolism estrone 17beta-estradiol 17beta-hydroxysteroid dehydrogenase steroid sulfatase steroid sulfotransferase aromatase serum hormone levels endometrial tissue
- The Netherlands
- 2016-03-20
Not Recruiting
- A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - NA
- This study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in line with Americian Association recommendations. MedDRA version: 8.1 Level: LLT Classification code 10055026 Term: Prostatic obstruction
- Germany, Ireland, United Kingdom
- 2006-07-25
Recruiting
- Sexual dysfunction and fertility-related distress in young adult survivors of childhood cancer
- Sexual dysfunction and fertility-related distress in young adult (19-40 years of age) survivors of childhood cancer (diagnosis at 0-17 years of age, including all malignant diagnoses and brain tumors) Mental and Behavioural Disorders
- Sweden
- 2019-11-27
Authorised
- Fertility preservation in breast cancer patients: oocytes or embryos vitrification.
- The aim of this trial is to offer a safe and efficient alternative protocol to preserve fertility by storing oocytes in breast cancer patients before chemotherapy. Letrozole, an inhibitor of aromatase, is administered during standard gonadotropins ovarian stimulation to maintain a low estradiol level during ovarian stimulation in patients with hormono-sensitive tumour. MedDRA version: 18.1 Level: LLT Classification code 10006190 Term: Breast cancer invasive NOS System Organ Class: 100000004864 MedDRA version: 18.1 Level: LLT Classification code 10016465 Term: Fertility female decreased System Organ Class: 100000004872 MedDRA version: 18.1 Level: LLT Classification code 10016463 Term: Fertility decreased female System Organ Class: 100000004872 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium
- 2012-09-03
Authorised
- Afatinib as second-line therapy for lung cancer with EGFR mutation
- Metastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R) MedDRA version: 17.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Algeria, Egypt, Malaysia, Philippines, Poland, Romania, Serbia, Thailand, Tunisia
- 2014-07-02
Authorised
- A global study to assess the effects of osimertinib following chemoradiation in patients with Stage III unresectable non-small cell lung cancer (LAURA).
- Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation. MedDRA version: 20.0 Level: PT Classification code 10029519 Term: Non-small cell lung cancer stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, China, India, Japan, Korea, Republic of, Spain, Taiwan, Thailand, Turkey, United States, Vietnam
- 2018-06-21
Not Recruiting
- Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lung cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor. - MuTAR
- Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC who have not received previous chemotherapy for their disease and who present activating mutations in the TK domain of the EGFR. Any patient with locally advanced or metastatic non-small cell lung cancer disease found to have an EGFR Exon 19 deletion or exon 21 substitution L858R in the TK domain of EGFR gene will be offered first-line treatment with erlotinib.
- Portugal
- 2010-11-05
Authorised
- A research study to compare the combined treatment of osimertinib and bevacizumab with osimertinib treatment alone in patients with lung cancer that has progressed or spread to other parts of the body (metastatic) and with confirmed specific gene mutations (changes) in the epithelial growth factor receptor (EGFR)
- Patients with locally advanced or metastatic (stage IIIb-IVb) EGFRm (exon 19 deletion or exon 21 L858R) NSCLC with T790M resistance mutation at progression on prior EGFR TKI therapy MedDRA version: 19.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Ireland, Korea, Republic of, Netherlands, Singapore, Spain, Switzerland
- 2017-03-31
Authorised
- A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in patients with Non–Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor–Activating Mutations
- Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, exon 21 L858R mutations, or point mutations at position 719. Enrolled subjects must have a life expectancy of at least 12 weeks and have adequate liver, kidney, and bone marrow function. MedDRA version: 18.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.0 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, European Union, Hong Kong, Israel, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States
- 2015-09-25
